Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.

BACKGROUND AND AIM:Among various symptoms accompanied with chronic liver disease, pruritus affects the quality of life of patients, causing physical and mental stress, and worsens hepatic function. Recently, κ-opioid receptor agonist, nalfurafine hydrochloride was approved to treat central pruritus...

Full description

Bibliographic Details
Main Authors: Kenya Kamimura, Takeshi Yokoo, Hiroteru Kamimura, Akira Sakamaki, Satoshi Abe, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5467861?pdf=render
id doaj-037b9640ad714470b82de786dd5ed878
record_format Article
spelling doaj-037b9640ad714470b82de786dd5ed8782020-11-24T21:54:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017899110.1371/journal.pone.0178991Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.Kenya KamimuraTakeshi YokooHiroteru KamimuraAkira SakamakiSatoshi AbeAtsunori TsuchiyaMasaaki TakamuraHirokazu KawaiSatoshi YamagiwaShuji TeraiBACKGROUND AND AIM:Among various symptoms accompanied with chronic liver disease, pruritus affects the quality of life of patients, causing physical and mental stress, and worsens hepatic function. Recently, κ-opioid receptor agonist, nalfurafine hydrochloride was approved to treat central pruritus in patients with liver disease in Japan. This study aimed to assess the long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients. METHODS:A patient-reported outcome using questionnaire-based methods was used for 41 liver disease patients with or without pruritus symptoms. Nalfurafine hydrochloride (2.5 μg/day) was orally administered to 18 patients suffering from pruritus symptoms and whose current treatment was not effective. The same questionnaires and visual analogue scales (VAS) were repeatedly followed up for the patients for the entire follow-up period, and biochemical analyses were performed to evaluate the safety of the treatment. RESULTS:Pruritus completely disappeared in seven of 18 cases, and VAS scores showed a decreasing trend over time from the start of nalfurafine hydrochloride administration in all patients who received the medication. Among 11 patients who were followed up for more than 12 weeks, nine patients showed continuous improvement of symptoms, and this progress was still apparent at ≥20 weeks after starting administration (p < 0.0001). The medication was discontinued in four patients because of progression of primary disease, high cost, oral dryness, and anemia. No significant toxicity was observed on the serum biochemical analyses. CONCLUSIONS:Nalfurafine hydrochloride contributed to long-term suppression of pruritus without significant safety problems.http://europepmc.org/articles/PMC5467861?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kenya Kamimura
Takeshi Yokoo
Hiroteru Kamimura
Akira Sakamaki
Satoshi Abe
Atsunori Tsuchiya
Masaaki Takamura
Hirokazu Kawai
Satoshi Yamagiwa
Shuji Terai
spellingShingle Kenya Kamimura
Takeshi Yokoo
Hiroteru Kamimura
Akira Sakamaki
Satoshi Abe
Atsunori Tsuchiya
Masaaki Takamura
Hirokazu Kawai
Satoshi Yamagiwa
Shuji Terai
Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
PLoS ONE
author_facet Kenya Kamimura
Takeshi Yokoo
Hiroteru Kamimura
Akira Sakamaki
Satoshi Abe
Atsunori Tsuchiya
Masaaki Takamura
Hirokazu Kawai
Satoshi Yamagiwa
Shuji Terai
author_sort Kenya Kamimura
title Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
title_short Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
title_full Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
title_fullStr Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
title_full_unstemmed Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
title_sort long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description BACKGROUND AND AIM:Among various symptoms accompanied with chronic liver disease, pruritus affects the quality of life of patients, causing physical and mental stress, and worsens hepatic function. Recently, κ-opioid receptor agonist, nalfurafine hydrochloride was approved to treat central pruritus in patients with liver disease in Japan. This study aimed to assess the long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients. METHODS:A patient-reported outcome using questionnaire-based methods was used for 41 liver disease patients with or without pruritus symptoms. Nalfurafine hydrochloride (2.5 μg/day) was orally administered to 18 patients suffering from pruritus symptoms and whose current treatment was not effective. The same questionnaires and visual analogue scales (VAS) were repeatedly followed up for the patients for the entire follow-up period, and biochemical analyses were performed to evaluate the safety of the treatment. RESULTS:Pruritus completely disappeared in seven of 18 cases, and VAS scores showed a decreasing trend over time from the start of nalfurafine hydrochloride administration in all patients who received the medication. Among 11 patients who were followed up for more than 12 weeks, nine patients showed continuous improvement of symptoms, and this progress was still apparent at ≥20 weeks after starting administration (p < 0.0001). The medication was discontinued in four patients because of progression of primary disease, high cost, oral dryness, and anemia. No significant toxicity was observed on the serum biochemical analyses. CONCLUSIONS:Nalfurafine hydrochloride contributed to long-term suppression of pruritus without significant safety problems.
url http://europepmc.org/articles/PMC5467861?pdf=render
work_keys_str_mv AT kenyakamimura longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT takeshiyokoo longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT hiroterukamimura longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT akirasakamaki longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT satoshiabe longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT atsunoritsuchiya longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT masaakitakamura longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT hirokazukawai longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT satoshiyamagiwa longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
AT shujiterai longtermefficacyandsafetyofnalfurafinehydrochlorideonpruritusinchronicliverdiseasepatientspatientreportedoutcomebasedanalyses
_version_ 1725869040269787136